Published Date: 2021-06-14
Request a sample
APAC Animal Model Market size is predicted to reach USD 6.5 billion by 2027, according to a latest forecast report by Graphical Research.
Rising geriatric population coupled with increasing prevalence of chronic ailments in the Asia Pacific region is promoting the use of animal drug development practice. Exponential growth of population in the region has overburdened the resources required for development of drugs. This has resulted in an increased demand in pharmaceutical research and development activities to boost the production of affordable therapeutics and development of novel medical technologies. The pharmaceutical firms are emphasizing on utilizing animal models for treatment of rare diseases including osteoarthritis, cardiomyopathy and others. These companies are also investing in healthcare research in order to discover new resources to develop efficient therapeutics and meet the rising demand of population in the region.
Growing research and development expenses in the biotechnology and pharmaceutical sector, ongoing innovations in animal models and rising number of clinical trials are driving the industry growth in the region. As per the World Health Organization (WHO), the number of registered clinical studies in South East Asia was about 92% in 2019. Diseases animal models are regarded as essential tool in clinical research studies and drug development for rare diseases. According to a research, there has been significant increase in the pharmaceutical research in Asia Pacific region in the past decade. Companies including GSK, AstraZeneca, Pfizer and Merck are investing in emerging economies in the region. For instance, China is quickly progressing as a pharmaceutical hub. Several prominent pharmaceutical players such as Eli Lilly, J&J, Novartis, Roche, Sanofi and others are increasing their operational presence and collaborating with local institutions in the country. Thus, the rise in biopharmaceutical research and development activities has augmented the demand for animal models.
Based on animal type, the market is segmented as mice, rats, fish, birds, cattle, pigs, amphibians, guinea pigs, dogs, cats, rabbits, monkeys, sheep, hamsters and others. Mice segment accounted for more than USD 819 million in 2020 and dominated the market. The majority market share is owing to relatively high similarities in phylogenetic and physiological aspects with humans. The use of mice animal model is rapidly rising as mice and humans have around 95% of similarity in DNA and hence, is used in broad range of applications in oncology, immunology and inflammation, cardiovascular, and diabetes studies. Due to ongoing COVID-19 pandemic mice models are extensively being used in laboratories and biopharmaceutical industry for SARS-CoV-2 related study. As per the research study published by the National Centers for Biotechnology Information (NCBI) in July 2020, the researchers reported infecting a mice using SARS-CoV-2 strain. The infected mice was further used to help in demonstrating effects of COVID-19 vaccine and others.
Based on technology, the animal model market is segmented as CRISPR, microinjection, embryonic stem cell injection, nuclear transfer and other. Microinjection segment is projected to expand at a CAGR of 7.3% from 2021 to 2027. Microinjection is utilized in development of transgenic organisms by transferring genetic material in nucleus of the fertilized oocyte. These animals play an increasingly important role in research concerned with numerous therapeutic areas including cardiovascular and atherosclerosis research. The advent of microinjection technology has facilitated culturing and manipulation of mammalian embryos. Microinjection approach is also used in order to study the characteristics of genes with the help of mice animal models. This approach is considered as relatively reliable and finds applications in different species.
Browse detailed statistical insights from the report, “Asia Pacific Animal Model Market Forecast 2027 By End-use (Companies {Pharmaceutical, Biotechnology, Cosmetics}, Organizations {Government, Non-government}, Academic and Research Institutes, Contract Research Organizations (CRO)), By Animal Type (Mice, Rats, Fish, Birds, Cattles, Pigs, Amphibians, Guinea Pigs, Dogs, Cats, Rabbits, Monkeys, Sheep, Hamsters), By Technology (CRISPR, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer), By Application (Research & Development {Infectious Disease, Immunological Diseases, Cancer, Cardiovascular Diseases, Diabetes, Genetic Diseases, Neurological Diseases, Obesity, NAFLD/NASH, Renal Disease, Diabetic Eye Disease, Fibrosis, Microbiome}, Production and Quality Control, Academics, Preclinical Applications {Infectious Disease, Immunological Diseases, Cancer, Cardiovascular Diseases, Diabetes, Genetic Diseases, Neurological Diseases, Obesity, NAFLD/NASH, Renal Disease, Diabetic Eye Disease, Fibrosis, Microbiome}), By Use (Human, Veterinary), Research Report, Regional Outlook (China, Japan, Australia, South Korea, New Zealand, Taiwan), COVID-19 Impact Statistics, Price Trends, Historic Data, Growth Prospects, Competitive Industry Share” along with the table of contents (ToC) @
https://www.graphicalresearch.com/industry-insights/1852/asia-pacific-animal-model-market
Based on application, the animal model market is bifurcated as research and development, production and quality control, academics, preclinical applications and others. Preclinical applications segment was valued at over USD 382 million in 2020 and anticipated to expand at a CAGR of 8.6% from 2021 to 2027. The substantial growth of the segment is owing to use of animal models in confirming the efficacy of the candidate drug and evaluation of acute toxicity. The animal models are considered as a fundamental tool that aids in making the decision regarding assessment of potential therapies in preclinical studies. Preclinical studies using animal model unquestionably offer comprehensive data and valuable insights on the clinical performance and properties of the candidate drug. Implementation of several safety parameters in animal models further assist in developing necessary safety data related to drug development. Strong reliance on the pharmaceutical discovery and development approach in oncology using animal models has increasingly proven to be beneficial. These animal models help in mimicking the heterogeneity of human cancers and further helps in demonstrating optimal dosing and drug combinations for use in clinical trials.
Based on use, the market is segmented as human and veterinary. Veterinary segment is anticipated to expand at 7.2% CAGR from 2021 to 2027. The growth of the segment is attributable to rising incidence of animal disorders and infections promoting the rising interest to develop veterinary vaccines and medications. The emergence and spread of zoonotic disorders from wild animals is growing exponentially. Several diseases such as highly pathogenic avian influenza, severe acute respiratory syndrome, hemorrhagic fever and Rift Valley fever has caused significant damage to livestock and pets. Owing to emergent or re-emerging zoonoses and other animal infections, there is growing interest for developing therapeutics for these ailments. Animal models address a broad range of applications related to development and assessment of novel therapies or vaccines. The use of animals is based on the fact that human ailments also affect other species. The animal model mechanisms often help in research associated with veterinary drugs.
Based on end-use, the market is segmented as companies, organizations, academic & research institutes and contract research organizations (CROs). Contract research organizations segment held considerable market share in 2020 and was valued at more than USD 288 million. The considerable market share is attributable to the growing R&D activities, shrinking productivity, intense competition from generics and complex regulatory scenario. Furthermore, high rate failure of candidate drugs in later stage clinical studies results in waste of capital, time as well as resources for the drug manufacturers. Henceforth, the pharmaceutical and biotech firms are outsourcing drug development activities. CROs provide numerous advantages such as high accuracy in conducting in vivo studies, fast allocation of space in animal facilities and provide highly skilled staff to implement designated experiments. These organizations specializing in animal models also provide better navigation through the essential animal protocols.
Japan animal model market is anticipated to expand at 7.9% CAGR and reach over USD 2,317 million by 2027. The higher market growth in the country is owing to the increase in research and development activities in biomedical & regenerative medicine field and well-developed healthcare infrastructure in the country. It provides intellectual property protection, transparent systems, high compliance and favorable government initiatives. Expenditure in the country is relatively higher by Asian standards. The Japanese government is further trying to attract global players operating chronic disease research, regenerative medicine, and pharmacogenomics. Firms engaged in precision medicine also benefit by Japan Revitalization Strategy and Healthcare Policy. These policies implemented by the government will promote the use of animal models in precision medicine and pharmacogenomics.
The APAC animal model market research report includes in-depth coverage of the industry with estimates & forecast in terms of revenue in USD million from 2016 to 2027, for the following segments:
Asia Pacific Market, By Animal Type
Asia Pacific Market, By Technology
Asia Pacific Market, By Application
Asia Pacific Market, By Use
Asia Pacific Market, By End-use
The above information has been provided for the following countries:
The great explorer of the truth, the master-builder of human happiness no one rejects dislikes avoids pleasure itself because it is pleasure but because know who do not those how to pursue pleasures rationally encounter consequences that are extremely painful desires to obtain.
Read More